LIVIVO - Search results -

Search results

Result 1 - 10 of total 20

Search options

Book ; Thesis: Der Metabolismus des Schwangerschaftshormons Progesteron in der menschlichen Niere

Johanssen, Sarah

2003

Author's details	vorgelegt von Sarah Johanssen
Language	German
Size	90 Bl. : graph. Darst.
Publishing country	Germany
Document type	Book ; Thesis
Thesis / German Habilitation thesis	Berlin, Freie Univ., Diss., 2003
HBZ-ID	HT013942751
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2003 D 2452	order for loan	Magazin

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Validierung der deutschen Übersetzung der Centrality of Event Scale (CES-G)

Conen, Lisa / Johanßen, Helen / Ülsmann, Dominik / Ertle, Andrea / Schulte, Sarah / Fydrich, Thomas / Schulte-Herbrüggen, Olaf

Zeitschrift für Klinische Psychologie und Psychotherapie

2022 Volume 51, Issue 1, Page(s) 47–55

Abstract: Theoretischer Hintergrund: Eine wachsende Zahl von Forschungsarbeiten weist auf die Bedeutung der wahrgenommenen Zentralität eines traumatischen Ereignisses in der eigenen Lebensgeschichte für das Verständnis von Symptomen der Posttraumatischen ... ...

Title translation	Validation of a German translation of the Centrality of Event Scale (CES-G)
Abstract	Theoretischer Hintergrund: Eine wachsende Zahl von Forschungsarbeiten weist auf die Bedeutung der wahrgenommenen Zentralität eines traumatischen Ereignisses in der eigenen Lebensgeschichte für das Verständnis von Symptomen der Posttraumatischen Belastungsstörung (PTBS) hin. Zur Untersuchung dieser Beziehung exisitert bislang noch kein Messinstrument, das die Ereigniszentralität auf Deutsch erfasst. Fragestellung: Um die Forschung auf diesem Gebiet im deutschsprachigen Raum zu ermöglichen, wird die Centrality of Event Scale (CES; Berntsen & Rubin, 2006) in einer deutschen Übersetzung (CES-G) vorgestellt und hinsichtlich ihrer psychometrischen Eigenschaften untersucht. Methode: Zur psychometrischen Auswertung wurde die CES-G 322 Studierenden sowie 115 ambulanten Patientinnen und Patienten mit ausgeprägter PTBS-Symptomatik vorgelegt. Ergebnisse: Die CES-G zeigt eine hervorragende interne Konsistenz, substanzielle Korrelationen mit Maßen von PTBS-Symptomen, allgemeiner Psychopathologie, Depressivität und maladaptiven kognitiven Prozessen sowie eine kriterienbezogene Validität bezüglich PTBS Symptomen in einer klinischen Stichprobe. Schlussfolgerungen: Die deutsche Übersetzung der CES ist ein verlässliches und valides Messinstrument für Ereigniszentralität.
Keywords	Criterion Validity ; Factor Structure ; Faktorenstruktur ; Foreign Language Translation ; Fremdsprachenübersetzung ; Gedächtnis ; Internal Consistency ; Interne Konsistenz ; Kriteriumsvalidität ; Lebensereignisse ; Life Experiences ; Memory ; Posttraumatic Stress Disorder ; Posttraumatische Belastungsstörung ; Rating Scales ; Rating-Skalen ; Test Construction ; Test Reliability ; Test Validity ; Testkonstruktion ; Testreliabilität ; Testvalidität ; Trauma
Language	German
Document type	Article
ZDB-ID	2002367-4
ISSN	1616-3443 ; 0084-5345
ISSN	1616-3443 ; 0084-5345
DOI	10.1026/1616-3443/a000651
Database	PSYNDEX

In stock of ZB MED Cologne/Königswinter

Zs.A 947: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Microbubbles Containing Lysolipid Enhance Ultrasound-Mediated Blood-Brain Barrier Breakdown In Vivo.

Vince, Oliver / Peeters, Sarah / Johanssen, Vanessa A / Gray, Michael / Smart, Sean / Sibson, Nicola R / Stride, Eleanor

Advanced healthcare materials

2020 Volume 10, Issue 3, Page(s) e2001343

Abstract: Ultrasound and microbubbles (MBs) offer a noninvasive method of temporarily enhancing blood-brain barrier (BBB) permeability to therapeutics. To reduce off-target effects, it is desirable to minimize the ultrasound pressures required. It has been shown ... ...

Abstract	Ultrasound and microbubbles (MBs) offer a noninvasive method of temporarily enhancing blood-brain barrier (BBB) permeability to therapeutics. To reduce off-target effects, it is desirable to minimize the ultrasound pressures required. It has been shown that a new formulation of MBs containing lysolipids (Lyso-MBs) can increase the cellular uptake of a model drug in vitro. The aim of this study is to investigate whether Lyso-MBs can also enhance BBB permeability in vivo. Female BALB/c mice are injected with either Lyso-MBs or control MBs and gadolinium-DTPA (Gd-DTPA) and exposed to ultrasound (500 kHz, 1 Hz pulse repetition frequency, 1 ms pulse length, peak-negative pressures 160-480 kPa) for 2 min. BBB permeabilization is measured via magnetic resonance imaging (7.0 T) of Gd-DTPA extravasation and subsequent histological examination of brain tissue to assess serum immunoglobulin G (IgG) extravasation (n = 8 per group). An approximately twofold enhancement in BBB permeability is produced by the Lyso-MBs at the highest ultrasound pressure compared with the control. These findings indicate that modifying the composition of phospholipid-shelled MBs has the potential to improve the efficiency of BBB opening, without increasing the ultrasound pressure amplitude required. This is particularly relevant for delivery of therapeutics deep within the brain.
MeSH term(s)	Animals ; Blood-Brain Barrier/diagnostic imaging ; Drug Delivery Systems ; Female ; Magnetic Resonance Imaging ; Mice ; Mice, Inbred BALB C ; Microbubbles ; Ultrasonography
Language	English
Publishing date	2020-11-16
Publishing country	Germany
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2649576-4
ISSN	2192-2659 ; 2192-2640
ISSN (online)	2192-2659
ISSN	2192-2640
DOI	10.1002/adhm.202001343
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6966: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Mifepristone (RU 486) in Cushing's syndrome.

Johanssen, Sarah / Allolio, Bruno

European journal of endocrinology

2007 Volume 157, Issue 5, Page(s) 561–569

Abstract: Context: Mifepristone (RU 486) blocks the action of cortisol by binding to the glucocorticoid receptor and, therefore, is of potential therapeutic value in Cushing's syndrome. However, research in endogenous hypercortisolism has been hampered by the ... ...

Abstract	Context: Mifepristone (RU 486) blocks the action of cortisol by binding to the glucocorticoid receptor and, therefore, is of potential therapeutic value in Cushing's syndrome. However, research in endogenous hypercortisolism has been hampered by the controversy related to the use of mifepristone for inducing abortion. Currently, new studies are planned to better define the role of RU 486 in Cushing's syndrome. This paper reviews the available evidence concerning the therapeutic effects and adverse events of RU 486 in Cushing's syndrome. Evidence acquisition: Original articles and reviews were identified using a PubMed search strategy covering the time period until February 2007. Evidence synthesis: Treatment of Cushing's syndrome with mifepristone has been reported in a total of 18 patients, with daily doses ranging from 5 to 30 mg/kg. Case reports indicate that the mifepristone-induced receptor blockade may lead to significant clinical improvement in patients with Cushing's syndrome in whom surgery and inhibitors of adrenal steroidogenesis fail to control hypercortisolism. Due to its rapid onset of action, mifepristone may be particularly useful in acute crises, e.g. in cortisol-induced psychosis. Side effects include adrenal insufficiency and, as a result of its antiprogestin action, endometrial hyperplasia in long-term treatment. Adrenal insufficiency can be assessed only by careful clinical evaluation, as the hormonal parameters are not reliable during receptor blockade, and is rapidly reversed by exogenous dexamethasone. Well-designed larger clinical trials are needed to better assess the value of this interesting drug in the treatment of Cushing's syndrome.
MeSH term(s)	Animals ; Cushing Syndrome/drug therapy ; Cushing Syndrome/metabolism ; Humans ; Mifepristone/adverse effects ; Mifepristone/chemistry ; Mifepristone/therapeutic use
Chemical Substances	Mifepristone (320T6RNW1F)
Language	English
Publishing date	2007-11
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	1183856-5
ISSN	1479-683X ; 0804-4643
ISSN (online)	1479-683X
ISSN	0804-4643
DOI	10.1530/EJE-07-0458
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.147: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey.

Elbelt, Ulf / Schlaffer, Sven M / Buchfelder, Michael / Knappe, Ulrich J / Vila, Greisa / Micko, Alexander / Deutschbein, Timo / Unger, Nicole / Lammert, Alexander / Topuzoglu-Müller, Tengü / Bojunga, Jörg / Droste, Michael / Johanssen, Sarah / Kolenda, Herbert / Ritzel, Katrin / Buslei, Rolf / Strasburger, Christian J / Petersenn, Stephan / Honegger, Jürgen

The Journal of clinical endocrinology and metabolism

2019 Volume 105, Issue 3

Abstract: Context: Despite growing evidence that temozolomide (TMZ) therapy is effective for the treatment of aggressive pituitary tumors (APTs) or carcinomas (PCs), individual therapy decisions remain challenging.: Objective: We therefore aimed to report on ... ...

Abstract	Context: Despite growing evidence that temozolomide (TMZ) therapy is effective for the treatment of aggressive pituitary tumors (APTs) or carcinomas (PCs), individual therapy decisions remain challenging. Objective: We therefore aimed to report on clinical characteristics leading to initiation of TMZ therapy and to add evidence on TMZ long-term effectiveness. Design and subjects: Retrospective survey on TMZ treatment in patients with APTs or PCs. TMZ therapy was initiated in 47 patients (22 females) with APTs (n = 34) or PCs (n = 13). Mean age at diagnosis was 45 ± 15 years. The immunohistochemical subtypes were corticotroph (n = 20), lactotroph (n = 18), and nonfunctioning (n = 9) tumors. TMZ therapy started 8 years after initial diagnosis using a standard regimen (median 6 cycles) for the majority of patients. Results: Long-term radiological response to TMZ after a median follow-up of 32 months with 4 patients still on TMZ therapy was tumor regression for 9 (20%), stable disease for 8 (17%), and tumor progression for 29 patients (63%) (outcome data available for 46 patients). Progression occurred 16 months after initiation of TMZ. Median estimated progression-free survival was 23 months. Disease stabilization and median progression-free survival did not differ between patients with APTs or PCs. Predictors of tumor response were not identified. Overall, TMZ was well tolerated. Conclusion: We performed a nationwide survey on TMZ therapy in patients with APTs and PCs. While early response rates to TMZ are promising, long-term outcome is less favorable. Prolonged TMZ administration should be considered. We were not able to confirm previously reported predictors of tumor response to TMZ.
MeSH term(s)	Adenoma/drug therapy ; Adult ; Antineoplastic Agents, Alkylating/therapeutic use ; Carcinoma/drug therapy ; Female ; Germany ; Humans ; Male ; Middle Aged ; Pituitary Neoplasms/drug therapy ; Retrospective Studies ; Temozolomide/therapeutic use ; Treatment Outcome
Chemical Substances	Antineoplastic Agents, Alkylating ; Temozolomide (YF1K15M17Y)
Language	English
Publishing date	2019-11-19
Publishing country	United States
Document type	Evaluation Study ; Journal Article
ZDB-ID	3029-6
ISSN	1945-7197 ; 0021-972X
ISSN (online)	1945-7197
ISSN	0021-972X
DOI	10.1210/clinem/dgz211
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.134: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: The yield of wireless capsule endoscopy in the detection of neuroendocrine tumors in comparison with CT enteroclysis.

Johanssen, Sarah / Boivin, Mariam / Lochs, Herbert / Voderholzer, Winfried

Gastrointestinal endoscopy

2006 Volume 63, Issue 4, Page(s) 660–665

Abstract: Background: Patients with neuroendocrine tumors (NET) of the small bowel often present with metastatic disease, and localization of the primary tumor still is a diagnostic challenge. Wireless capsule endoscopy (WCE) is an established method that ... ...

Abstract	Background: Patients with neuroendocrine tumors (NET) of the small bowel often present with metastatic disease, and localization of the primary tumor still is a diagnostic challenge. Wireless capsule endoscopy (WCE) is an established method that improves the diagnostic evaluation of diseases of the small intestine. Objective: The aim of this study was to determine the diagnostic accuracy of WCE in imaging neuroendocrine tumors of the small bowel in these patients. Design: We retrospectively compared the findings of capsule endoscopy to the findings of CT enteroclysis in patients with histopathological confirmation of NET. Patients: Eight patients with newly established diagnosis of metastatic NET were included. Interventions: All patients underwent CT enteroclysis and wireless capsule endoscopy within a maximum of 2 weeks. Main outcome measurements: Number of primary tumors detected. The results of surgery were used as a gold standard for both methods. Results: CT enteroclysis detected the primary tumor in 4 of 8 patients whereas WCE found the primary in 3 patients. On the contrary, CT enteroclysis provided more false-positive results. Limitations: Frequent extraluminal tumor growth. Conclusions: In patients with NET, wireless capsule endoscopy may be helpful in individual cases but the general diagnostic value of this method may be limited due to frequent extraluminal growth of these tumors.
MeSH term(s)	Adult ; Aged ; Diagnosis, Differential ; Endoscopes, Gastrointestinal/statistics & numerical data ; Endoscopy, Gastrointestinal/methods ; Endoscopy, Gastrointestinal/statistics & numerical data ; Equipment Design ; Female ; Follow-Up Studies ; Humans ; Ileal Neoplasms/diagnostic imaging ; Ileal Neoplasms/pathology ; Male ; Middle Aged ; Miniaturization/instrumentation ; Neuroendocrine Tumors/diagnostic imaging ; Neuroendocrine Tumors/pathology ; Reproducibility of Results ; Retrospective Studies ; Telemedicine/methods ; Telemedicine/statistics & numerical data ; Tomography, X-Ray Computed/methods
Language	English
Publishing date	2006-04
Publishing country	United States
Document type	Comparative Study ; Evaluation Studies ; Journal Article
ZDB-ID	391583-9
ISSN	1097-6779 ; 0016-5107
ISSN (online)	1097-6779
ISSN	0016-5107
DOI	10.1016/j.gie.2005.11.055
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 283: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 519: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report.

Davis, Chris / Tipton, Tom / Sabir, Suleman / Aitken, Celia / Bennett, Susan / Becker, Stephan / Evans, Tom / Fehling, Sarah Katharina / Gunson, Rory / Hall, Yper / Jackson, Celia / Johanssen, Ingolfur / Kieny, Marie Paule / Mcmenamin, Jim / Spence, Elizabeth / Strecker, Thomas / Sykes, Catie / Templeton, Kate / Thorburn, Fiona /

Peters, Erica / Henao Restrepo, Ana Maria / White, Beth / Zambon, Maria / Carroll, Miles W / Thomson, Emma C

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

2019 Volume 71, Issue 11, Page(s) 2872–2879

Abstract: Background: In October 2015, 65 people came into direct contact with a healthcare worker presenting with a late reactivation of Ebola virus disease (EVD) in the United Kingdom. Vaccination was offered to 45 individuals with an initial assessment of high ...

Abstract	Background: In October 2015, 65 people came into direct contact with a healthcare worker presenting with a late reactivation of Ebola virus disease (EVD) in the United Kingdom. Vaccination was offered to 45 individuals with an initial assessment of high exposure risk. Methods: Approval for rapid expanded access to the recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) vaccine as an unlicensed emergency medicine was obtained from the relevant authorities. An observational follow-up study was carried out for 1 year following vaccination. Results: Twenty-six of 45 individuals elected to receive vaccination between 10 and 11 October 2015 following written informed consent. By day 14, 39% had seroconverted, increasing to 87% by day 28 and 100% by 3 months, although these responses were not always sustained. Neutralizing antibody responses were detectable in 36% by day 14 and 73% at 12 months. Common side effects included fatigue, myalgia, headache, arthralgia, and fever. These were positively associated with glycoprotein-specific T-cell but not immunoglobulin (Ig) M or IgG antibody responses. No severe vaccine-related adverse events were reported. No one exposed to the virus became infected. Conclusions: This paper reports the use of the rVSV-ZEBOV vaccine given as an emergency intervention to individuals exposed to a patient presenting with a late reactivation of EVD. The vaccine was relatively well tolerated, but a high percentage developed a fever ≥37.5°C, necessitating urgent screening for Ebola virus, and a small number developed persistent arthralgia.
MeSH term(s)	Antibodies, Viral ; Ebola Vaccines/therapeutic use ; Ebolavirus ; Follow-Up Studies ; Hemorrhagic Fever, Ebola/prevention & control ; Humans ; Post-Exposure Prophylaxis ; Recurrence ; United Kingdom
Chemical Substances	Antibodies, Viral ; Ebola Vaccines
Language	English
Publishing date	2019-11-29
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S.
ZDB-ID	1099781-7
ISSN	1537-6591 ; 1058-4838
ISSN (online)	1537-6591
ISSN	1058-4838
DOI	10.1093/cid/ciz1165
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1505: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 480: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.

Wortmann, Sebastian / Quinkler, Marcus / Ritter, Christian / Kroiss, Matthias / Johanssen, Sarah / Hahner, Stefanie / Allolio, Bruno / Fassnacht, Martin

European journal of endocrinology

2010 Volume 162, Issue 2, Page(s) 349–356

Abstract: Objective: No standard therapy for advanced adrenocortical carcinoma (ACC) is established by any randomized trial but a consensus conference 2003 recommended mitotane as monotherapy or combined with etoposide, doxorubicin and cisplatin or with ... ...

Abstract	Objective: No standard therapy for advanced adrenocortical carcinoma (ACC) is established by any randomized trial but a consensus conference 2003 recommended mitotane as monotherapy or combined with etoposide, doxorubicin and cisplatin or with streptozotocin as first-line systemic therapy. However, there is no evidence for any therapy beneficial in patients failing these therapies. Therefore, we evaluated the effects of the anti-VEGF antibody bevacizumab plus capecitabine as salvage therapy in ACC. Methods: Patients registered with the German ACC Registry with refractory ACC progressing after cytotoxic therapies were offered treatment with bevacizumab (5 mg/kg body weight i.v. every 21 days) and oral capecitabine (950 mg/m(2) twice daily for 14 days followed by 7 days of rest) in 2006-2008. Evaluation of tumour response was performed by imaging according to response evaluation criteria in solid tumours every 12 weeks. Results: Ten patients were treated with bevacizumab plus capecitabine. None of them experienced any objective response or stable disease. Two patients had to stop therapy after few weeks due to hand-foot syndrome, and three patients died on progressive disease within 12 weeks. Other adverse events were mild (grade I-II). Median survival after treatment initiation was 124 days. Conclusions: Bevacizumab plus capecitabine has no activity in patients with very advanced ACC. Hence, this regimen cannot be recommended as a salvage therapy.
MeSH term(s)	Adrenal Cortex Neoplasms/drug therapy ; Adrenocortical Carcinoma/drug therapy ; Adult ; Aged ; Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/adverse effects ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/adverse effects ; Bevacizumab ; Capecitabine ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives ; Drug Therapy, Combination ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Fluorouracil/analogs & derivatives ; Humans ; Male ; Middle Aged ; Salvage Therapy/methods ; Severity of Illness Index ; Survival Rate ; Treatment Failure ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Vascular Endothelial Growth Factor A/immunology
Chemical Substances	Angiogenesis Inhibitors ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antimetabolites, Antineoplastic ; VEGFA protein, human ; Vascular Endothelial Growth Factor A ; Deoxycytidine (0W860991D6) ; Bevacizumab (2S9ZZM9Q9V) ; Capecitabine (6804DJ8Z9U) ; Fluorouracil (U3P01618RT)
Language	English
Publishing date	2010-02
Publishing country	England
Document type	Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1183856-5
ISSN	1479-683X ; 0804-4643
ISSN (online)	1479-683X
ISSN	0804-4643
DOI	10.1530/EJE-09-0804
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.147: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Radiotherapy in adrenocortical carcinoma.

Polat, Buelent / Fassnacht, Martin / Pfreundner, Leo / Guckenberger, Matthias / Bratengeier, Klaus / Johanssen, Sarah / Kenn, Werner / Hahner, Stefanie / Allolio, Bruno / Flentje, Michael

Cancer

2009 Volume 115, Issue 13, Page(s) 2816–2823

Abstract: Adrenocortical carcinoma (ACC) is a rare malignancy, and patients with ACC have a poor prognosis. Even after radical surgery, up to 85% of patients develop recurrent disease. Systemic treatment options still have limited efficacy. Because the role of ... ...

Abstract	Adrenocortical carcinoma (ACC) is a rare malignancy, and patients with ACC have a poor prognosis. Even after radical surgery, up to 85% of patients develop recurrent disease. Systemic treatment options still have limited efficacy. Because the role of radiotherapy is not defined well and because ACC often is considered radioresistant, the authors reviewed the available data on radiotherapy for ACC. Original articles and reviews were identified using a PubMed search strategy that included the period up to July 2008. Ten articles were identified that covered radiotherapy in a total of 129 patients with ACC (64 patients received postoperative irradiation, and 65 patients received palliative therapy for advanced disease). In addition, 26 patients were identified in the German ACC Registry who received palliative radiotherapy. Furthermore, patterns of failure after adjuvant radiotherapy were investigated, and the authors provided recommendations for patient selection, treatment planning, and treatment protocols. In an adjuvant setting, postoperative radiotherapy was able to prevent local recurrence in the majority of patients. In those with advanced disease, a response to radiotherapy was observed in 57% of patients who received palliative radiotherapy. Therefore, the authors concluded that radiotherapy may play an important role in the care of patients with ACC. Until better evidence is available, the authors recommended the following approach: Adjuvant radiotherapy to the tumor bed should be considered in patients at high risk for local recurrence (eg, incomplete/R1 resection); a total dose of >40 grays (Gy) with single fractions of 1.8 Gy to 2 Gy should be administered (including a boost volume to reach from 50 Gy to 60 Gy in individual patients); and radiotherapy in a palliative setting may be used for symptomatic metastases to bone, brain, or vena cava obstruction. With state-of-the-art technology, acute and long-term toxicities mostly were mild to moderate. However, the authors concluded that prospective investigations would be required to fully define the therapeutic potential of this important treatment option.
MeSH term(s)	Adrenal Cortex Neoplasms/radiotherapy ; Adrenocortical Carcinoma/radiotherapy ; Combined Modality Therapy ; Humans ; Lymphatic Metastasis ; Neoplasm Recurrence, Local ; Palliative Care ; Radiation Injuries ; Radiotherapy, Adjuvant ; Recurrence ; Treatment Outcome
Language	English
Publishing date	2009-07-01
Publishing country	United States
Document type	Evaluation Studies ; Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	1429-1
ISSN	1097-0142 ; 0008-543X ; 1934-662X
ISSN (online)	1097-0142
ISSN	0008-543X ; 1934-662X
DOI	10.1002/cncr.24331
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.146: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine.

Quinkler, Marcus / Hahner, Stefanie / Wortmann, Sebastian / Johanssen, Sarah / Adam, Patrick / Ritter, Christian / Ritte, Christian / Strasburger, Christian / Allolio, Bruno / Fassnacht, Martin

The Journal of clinical endocrinology and metabolism

2008 Volume 93, Issue 6, Page(s) 2057–2062

Abstract: Context: Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis. In advanced disease, mitotane given as monotherapy or combined either with etoposide, doxorubicin, and cisplatin or with streptozotocin is the recommended first-line ... ...

Abstract	Context: Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis. In advanced disease, mitotane given as monotherapy or combined either with etoposide, doxorubicin, and cisplatin or with streptozotocin is the recommended first-line therapy. However, many patients have progressive disease despite treatment with these regimens. Objective: Our objective was to evaluate the efficacy of the epidermal growth factor receptor inhibitor erlotinib plus gemcitabine as salvage therapy in ACC patients with very advanced ACC. Design/setting: The study consisted of case series collected from different centers (primary care and referral centers) in Germany in 2006-2007. Patients and intervention: Patients registered with the German ACC Registry with progressive ACC after two to four previous systemic therapies were offered treatment with erlotinib and gemcitabine. Oral erlotinib (100 mg/d) was administered on a daily basis and gemcitabine (800 mg/m(2)) iv every 14 d. Main outcome measure: We evaluated tumor response according to response evaluation criteria in solid tumors (RECIST) criteria after 12 wk of treatment. Results: Ten patients have been treated with erlotinib and gemcitabine. Only one in 10 patients experienced a minor response (progression-free survival 8 months), whereas eight patients had progressive disease at the first staging. One patient had to stop therapy after the first administration of gemcitabine due to cerebral seizure. Nine of 10 patients had died after a median of 5.5 months after treatment initiation. In addition to the seizure, one patient experienced severe pneumonia (grade III), and in one, gemcitabine administration had been delayed due to prolonged neutropenia. All other adverse events were mild (grade I-II). Conclusions: Salvage chemotherapy using erlotinib plus gemcitabine has very limited to no activity in patients with very advanced ACC.
MeSH term(s)	Adrenal Cortex Neoplasms/drug therapy ; Adrenal Cortex Neoplasms/pathology ; Adrenocortical Carcinoma/drug therapy ; Adrenocortical Carcinoma/pathology ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives ; Disease Progression ; Drug Administration Routes ; Drug Administration Schedule ; Erlotinib Hydrochloride ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Quinazolines/administration & dosage ; Quinazolines/adverse effects ; Salvage Therapy ; Treatment Outcome
Chemical Substances	Quinazolines ; Deoxycytidine (0W860991D6) ; gemcitabine (B76N6SBZ8R) ; Erlotinib Hydrochloride (DA87705X9K)
Language	English
Publishing date	2008-06
Publishing country	United States
Document type	Clinical Trial ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	3029-6
ISSN	1945-7197 ; 0021-972X
ISSN (online)	1945-7197
ISSN	0021-972X
DOI	10.1210/jc.2007-2564
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.134: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito